Question · Q4 2025
Matt asked about the prioritization of the in vivo versus ESCAPE next-generation sickle cell programs, the factors influencing the choice of the right next-gen program, and confidence in the in vivo program and its HSC targeting approach.
Answer
CEO John Evans and President Giuseppe Pino Ciaramella explained that in vivo LNP delivery offers easier administration and potential for broader patient reach if efficacy is proven. They noted progress in preclinical studies suggesting rapid clinical advancement and highlighted opportunities to enhance engraftment rates with ESCAPE-like technology, giving confidence in moving the in vivo program forward quickly.
Ask follow-up questions
Fintool can predict
BEAM's earnings beat/miss a week before the call


